Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02216890 · ClinicalTrials.gov registry record · Phase 1
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02216890 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 38 participants.
The verdict
NCT02216890, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.
Interventions
- DRUG SGN-CD70A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02216890
The ClinicalTrials.gov registry entry for NCT02216890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD70A is the first listed.
NCT02216890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02216890 about?
NCT02216890 is a clinical study titled "Safety Study of SGN-CD70A in Cancer Patients". This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without ca...
What is the current status of trial NCT02216890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-08. Estimated completion is 2017-02-15.
What interventions are being tested in trial NCT02216890?
The interventions under investigation include: SGN-CD70A (DRUG).
Who is sponsoring clinical trial NCT02216890?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.